Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercialization.
As of June 30, 2024, we have a proven record for the delivery of more than 3500 projects and established cooperation with more than 1000 global clients. With our 4300+ skilled employees working across 20+ sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines.
Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363).